Until very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of age. Safe, effective vaccines are needed to protect this population, facilitate in-person learning and socialization, and contribute to herd immunity.

Matéria Original


BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans


Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis